Broijl A, Kersten M-J, Alemayehu WG, Levin M-D, de Weerdt O, Vellenga E, Meijer E, Wittebol S, Tanis BC, Cornelisse PB, Stevens-Kroef M, Bos GM, Wijermans PW, Lokhorst H, Sonneveld P. Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma. Haematologica 2016; 101(4):e149-e152; https://doi.org/10.3324/haematol.2015.132431.